The Cost of Complacency: A Harm Reduction Funding Crisis
Harm Reduction International releases its annual report exploring the state of harm reduction funding in low- and middle-income countries. More
In a policy brief, WHO gives an update on the parts of the Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care relevant for men who have sex with men. More
Treatment Action Group releases a trials tracker providing a compilation of ongoing and recently completed clinical trials on long-acting therapies for HCV, malaria, and opioid use and overdose prevention in the R&D pipeline. More
C-EHRN releases a policy brief providing an overview of the state of the art regarding Drug Consumption Rooms, as well as an overview of recommendations and examples of good practices for policymakers. More
Several Ministries of Health have written to Danaher requesting that the price of the tests for XDR-TB, HIV and hepatitis — currently priced at $14.90 per test cartridge — also be lowered to no more than $7.97. More
Unitaid’s funding to support the integration of hepatitis C testing and treatment in harm reduction services, while trialing the use of two underused products to prevent infection. More